• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Inhibiting complement regulators in cancer immunotherapy with bispecific mAbs.
【24h】

Inhibiting complement regulators in cancer immunotherapy with bispecific mAbs.

机译：用双特异性mAb抑制癌症免疫疗法中的补体调节剂。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Although monoclonal antibody (mAb)-mediated immunotherapy of cancer has been proven to be feasible for clinical use, success rates until now have been disappointing. One reason for this might be the overexpression of membrane-bound complement regulatory proteins (mCRPs) by tumour cells. As complement activation is an important effector mechanism induced by therapeutic mAbs, inhibition of complement activation by tumour cells might reduce therapeutic efficacy by decreasing direct complement-mediated lysis as well as complement-dependent cellular cytotoxicity. Modulation of the function of these mCRPs might be achieved with therapeutic bispecific (bi-)mAbs that target a tumour antigen and simultaneously block a major mCRP. Clinical results will probably increase with such bi-mAbs compared with monovalent antitumour mAbs. In this review the feasibility of this approach is discussed.
机译：尽管已证明单克隆抗体（mAb）介导的癌症免疫疗法可用于临床，但迄今为止成功率令人失望。造成这种情况的原因之一可能是肿瘤细胞过度表达了膜结合的补体调节蛋白（mCRP）。由于补体激活是由治疗性mAb诱导的重要效应器机制，因此肿瘤细胞抑制补体激活可能会通过减少直接的补体介导的裂解以及补体依赖性细胞毒性来降低治疗效果。这些mCRP功能的调节可通过靶向肿瘤抗原并同时阻断主要mCRP的治疗性双特异性（bi-）mAb实现。与单价抗肿瘤mAb相比，使用这种bi-mAb可能会提高临床效果。在这篇综述中，讨论了这种方法的可行性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号